| Identification | Back Directory | [Name]
1-Benzoxepin-5(2H)-one, 4-[(4-ethylphenyl)methylene]-3,4-dihydro-6,8-dimethoxy-, (4E)- | [CAS]
2408841-19-8 | [Synonyms]
PKM2-IN-3
1-Benzoxepin-5(2H)-one, 4-[(4-ethylphenyl)methylene]-3,4-dihydro-6,8-dimethoxy-, (4E)- | [Molecular Formula]
C21H22O4 | [MOL File]
2408841-19-8.mol | [Molecular Weight]
338.4 |
| Hazard Information | Back Directory | [Uses]
PKM2-IN-3 is an inhibitor of PKM2 kinase with an IC50 value of 4.1 μM. PKM2-IN-3 exhibits an anti-neuroinflammatory effect by inhibiting PKM2-mediated glycolysis and NLRP3 activation[1]. | [in vivo]
PKM2-IN-3 (1, 10 mg/kg; i.p.; daily for 3 days ) significantly reverses the LPS-induced mice behavior changes in open field test[1].
PKM2-IN-3 (1, 10 mg/kg; i.v.; injected at 4 hours and 24 hours after ischemia onset) reduces the infarct volume and improves neurological deficits of tMCAO rats[1]. | Animal Model: | LPS-induced mice (male 6-8 weeks old; 20.0-22.0 g)[1] | | Dosage: | 1, 10 mg/kg | | Administration: | i.p.; daily for 3 days | | Result: | Reversed the LPS-induced mice behavior changes in open field test. |
| Animal Model: | tMCAO Sprague-Dawley rats (Male 8-10 weeks old; 250.0-280.0 g)[1] | | Dosage: | 1, 10 mg/kg | | Administration: | i.v.; injected at 4 hours and 24 hours after ischemia onset | | Result: | Reduced the infarct volume and improved neurological deficits of tMCAO rats. |
| [IC 50]
PKM2: 4.1 μM (IC50) | [References]
[1] Gao CL, et al. Synthesis and Target Identification of Benzoxepane Derivatives as Potential Anti-Neuroinflammatory Agents for Ischemic Stroke. Angew Chem Int Ed Engl. 2020;59(6):2429-2439. DOI:10.1002/anie.201912489 |
|
|